Vortex Liquid Biopsy Solutions has been selected to represent the Cambridge x Manchester Partnership at Cambridge Tech Week 2026, following a highly competitive application process involving innovative companies from across the UK technology and life sciences sectors. Vortex will join a…
Combining CTC Analysis and Proteomics Reveals New Insights into Metastatic Breast Cancer
Combining CTC Analysis and Proteomics Reveals New Insights into Metastatic Breast Cancer A breakthrough prospective study has demonstrated how combining live circulating tumour cells (CTCs) captured from a blood sample with advanced blood protein profiling can help doctors monitor treatment response…
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park – Manchester, UK
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park – Manchester, UK Vortex Biotech Holdings Limited has officially opened its new state‑of‑the‑art laboratory facilities at Manchester Science Park, marking a major milestone in the company’s growth and its mission to…
Vortex Launches Clinical Study Using Liquid Biopsy Technology to Advance Cancer Monitoring
Study will explore how live circulating tumour cells captured from a blood sample can help doctors monitor treatment response and disease progression
Vortex Chosen as First Company in Expanded AstraZeneca Exchange Programme
Vortex Chosen as First Company in Expanded AstraZeneca Exchange Programme Partnership links the North of England with the Golden triangle to drive national economic growth Vortex Liquid Biopsy Solutions Ltd (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is…
Groundbreaking Liquid Biopsy Paves New Path for NHS Cancer Care
NHS England: NHS first in world to roll out ‘revolutionary’ blood test for cancer patients London, May 30, 2025 – A groundbreaking advance in cancer diagnostics in the UK, centred on the revolutionary “liquid biopsy” blood test, will transform treatment pathways…
Watch our recent webinar “Advancing Cancer Care with Liquid Biopsy”
Gain insights into the latest advancements in non-invasive cancer diagnostics. Our recent webinar explores how cutting-edge research in circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) is transforming oncology. The session details current liquid biopsy methods, their operational principles, the…
Vortex and University of Maryland Baltimore Partner to Revolutionise Cancer Research
London, UK – April 2, 2025 – Vortex Biotech Holdings, a leader in oncology liquid biopsy, today announced a significant collaboration with the University of Maryland Baltimore (UMB) to spearhead clinical investigations into Vortex’s innovative technology. This partnership promises to provide an…
High Profile Appointment of Nigel Brooksby as Non-Executive Chairman Of Vortex Biotech Holdings
London, UK – January 28, 2025 – Vortex Biotech Holdings, a pioneering oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as its new Non-Executive Chairman. This high-profile addition to Vortex’s leadership team signals a significant step forward…
Vortex expands liquid biopsy research at The London Cancer Hub’s Innovation Gateway
https://www.icr.ac.uk/about-us/icr-news/detail/new-medtech-firm-expands-liquid-biopsy-research-at-the-london-cancer-hub-s-innovation-gateway London, UK – 2 October 2023 – Vortex Biosciences, a company at the forefront of personalised cancer therapy development, has significantly expanded its presence at The London Cancer Hub’s Innovation Gateway. This move follows the earlier opening of a new laboratory…